Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure

Mari Katsumata1 · Nobuhito Hirawa1 · Koichiro Sumida2 · Minako Kagimoto2 · Yosuke Ebara2 · Yuki Okuyama2 · Megumi Fujita1 · Akira Fujiwara1 · Mayumi Kobayashi1 · Yosuke Kobayashi3 · Yuichiro Yamamoto1 · Sanae Saka1 · Keisuke Yatsu2 · Tetsuya Fujikawa4 · Yoshiyuki Toya2 · Gen Yasuda1 · Kouichi Tamura2 · Satoshi Umemura5

Received: 24 October 2016 / Accepted: 30 December 2016 / Published online: 11 February 2017
© The Author(s) 2017. This article is published with open access at Springerlink.com

Abstract

Background  Tolvaptan, a vasopressin V2 receptor blocker, has a diuretic effect for patients with heart failure. However, there were a few data concerning the effects of tolvaptan in patients with chronic kidney disease (CKD).

Methods  We retrospectively analyzed 21 patients with chronic heart failure and CKD. Tolvaptan was co-administered with other diuretics in-use, every day. We compared clinical parameters before and after the treatments with tolvaptan. Furthermore, we examined the correlations between baseline data and the change of body weight.

Results  Tolvaptan decreased the body weight and increased the urine volume (p=0.001). The urine osmolality significantly decreased throughout the study period. Urinary Na/Cr ratio and FENa changed significantly after 4 h, and more remarkable after 8 h (p=0.003, both). Serum creatinine increased slightly after 1 week of treatment (p=0.012). The alteration of body weight within the study period correlated negatively with the baseline urine osmolality (r=−0.479, p=0.038), the baseline urine volume (r=−0.48, p=0.028), and the baseline inferior vena cava diameter (IVCD) (r=−0.622, p=0.017). Hyponatremia was improved to the normal value, and the augmentations of the sodium concentration were negatively associated with the basal sodium levels (p=0.01, r=−0.546).

Conclusions  Tolvaptan is effective in increasing diuresis and improved hyponatremia, even in patients with CKD. The baseline urine osmolality, urine volume, and IVCD may be useful predictors for diuretic effects of tolvaptan.

Keywords  Chronic kidney disease · Tolvaptan · Urine osmolality · Hyponatremia

Introduction

Tolvaptan is an oral diuretic with a new mechanism which selectivity binds to the V2 receptor as an antagonist. V2 receptors are located in the renal collecting duct, where arginine vasopressin (AVP) binding to the V2 receptor leads to a rise in intracellular cAMP. This promotes renal water reabsorption via translocation of intracellular vesicles containing the water channel aquaporin-2 into the apical plasma membrane and increased transcription of aquaporin-2 [1]. The compound’s aquaretic effects by single administration were confirmed by an increase in urine volume and a decrease in urine osmolality, followed by an increase in serum sodium concentration [2]. Tolvaptan has been demonstrated to ameliorate congestion in patients with heart failure [3, 4] and to correct hyponatremia [5, 6].

Patients with advanced CKD cannot produce enough urine and often fall into volume overload. Loop diuretics are conventionally used for these patients. However, there are several adverse effects with taking loop diuretics. One
is electrolyte abnormalities, such as hypokalemia and hyponatremia [7]. On the other hand, tolvaptan has been reported to promote water excretion without changes in renal hemodynamics or sodium and potassium excretion [1].

However, the effects of tolvaptan on urine volume, and urinary and serum sodium excretions in advanced CKD patients were not yet clarified. Furthermore, the parameters which relate to body weight reduction were also not sufficiently evaluated. Thus, to clarify the effects of tolvaptan on body weight, and urinary and serum electrolytes, as well as to examine the predictors for efficacy, we retrospectively evaluated the medical records of CKD patients.

Materials and methods

Study subjects

This was a retrospective observational study. We included patients with CKD stage G3–5 and congestive heart failure, who were admitted to our hospital and received tolvaptan for excess body fluid, despite administration of the conventional diuretics between December 2010 and April 2015. The definition of CKD G3–5 was eGFR less than 60 ml/min/1.73 m² over 3 months despite the underlying disease. We excluded the following: patients undergoing hemodialysis and peritoneal dialysis, those whose dose of other diuretics increased during the observation period (3 days before and a week after tolvaptan administration), and a case of acute kidney injury. The initial tolvaptan dose was 15 mg/day, except one case that started at 3.75 mg/day.

Measurements

The main endpoints of this study were changes of body weight after 1 week administration of tolvaptan, and we compared average urine volume for 3 days before and for 7 days after treatment. In addition, we compared values of blood pressure, urine osmolality, urine gravity, urea sodium excretion calculated by spot urine (U-Na, mEq/gCr), fractional excretion of sodium (FENa), serum creatinine, estimated glomerular filtration rate (eGFR), serum sodium, B-type natriuretic peptide (BNP), human atrial natriuretic peptide (hANP), and antiatriuretic hormone (ADH) before and after the administration of tolvaptan. We obtained data of urine osmolality, urine gravity, U-Na, and FENa after tolvaptan treatment at 4, 8, and 24 h. eGFR was calculated using the equation proposed by the Japanese Society of Nephrology as follows; eGFR (ml/min/1.73 m²) = 194 × Cr⁻¹·⁰⁹⁴ × Age⁻⁰·²⁸⁷ × 0.739 (if female) [8]. We collected data of the ejection fraction and inferior vena cava diameter (IVCD) in the case that heart ultrasonography was performed before beginning tolvaptan. IVCD was visualized two-dimensionally and measured by M-mode echocardiography in expiration as described elsewhere [9]. In cases of discharge or drug interruption, the data at discontinuance were substituted.

Statistical analysis

The value of each measurement was expressed as the median (interquartile range). Comparisons of parameters between before and after treatment were analyzed with the Wilcoxon signed-rank test. Factors correlating with changes of body weight and S-Na were analyzed with the Spearman rank correlation coefficient. We considered a p value <0.05 as significant. Data analysis was performed with SPSS 23 statistical software (SPSS Inc., Chicago, IL, USA).

Results

Table 1 shows the clinical characteristics of the study subjects. The study consisted of 15 men and 6 women with a median age of 69 (interquartile range 60–76). Nineteen patients were in CKD stage 5; two patients were in stage 3a or 3b respectively. The median serum creatinine level just before administration of tolvaptan was 3.82 mg/dl (interquartile range 3.48–5.08). The average urine volume for 3 days before tolvaptan administration was distributed between 292 and 1900 ml/day, and the median of all cases was 975 ml/day. One patient was in NYHA IV and eleven patients were in NYHA III, and five were in NYHA II. Primary diseases included benign nephropathy (n=10), diabetic nephropathy (n=7), polycystic kidney disease (n=1), microscopic polyangitis (n=1), membranous nephropathy (n=1), and lupus nephritis (n=1). Patients were treated with the following diuretics: furosemide alone (median dose of 140 mg, interquartile range 80–200, n=17), spironolactone 25 mg/day and trichlormethiazide 1 mg/day (n=1); furosemide 40 or 320 mg/day and potassium canrenoate 400 mg/day (n=2); or spironolactone alone (25 mg/day, n=1). The renin–angiotensin–aldosterone system (RAAS) inhibitor was prescribed for 12 patients. Only 1 patient took digitalis.

Body weight decreased (p<0.001), and urine volume increased with tolvaptan treatment (p<0.001) (Table 2). Reflecting water diuresis, urine osmolality decreased significantly (Fig. 1a). The urine osmolality decreased after 4 h (p=0.001), and markedly at 8 h (p<0.001). The effects on urine osmolality continued throughout the study periods. The urine gravity significantly decreased 8 h (p=0.043, n=6) and 24 h (p=0.002, n=14), but not significant at 1 week (Table 2).
U-Na and FENa increased significantly after 4 h ($p=0.035$ and $p=0.022$, respectively). The alteration at 8 h was more remarkable ($p=0.003$ and $p=0.003$, respectively). The alteration at 24 h was not significant, but FENa after 1 week significantly increased ($p=0.019$) (Fig. 1b, c). The serum creatinine and serum sodium increased significantly after 1 week ($p=0.012$ and $p=0.002$, respectively), and eGFR decreased similarly ($p=0.008$) (Table 2). However, there were 7 cases in which serum creatinine level decreased. There were no differences in blood pressure, BNP, hANP, and ADH between the baseline and 1 week with tolvaptan treatment (Table 2).

We analyzed the relationship between body weight alteration and several parameters (Table 3). The
alteration of body weight after 1 week correlated significantly with the baseline urine osmolality ($r = -0.479$, $p = 0.038$), urine volume ($r = -0.48$, $p = 0.028$), and IVCD ($r = -0.622$, $p = 0.017$) (Fig. 2). The alteration of body weight did not correlated with the baseline and after body weight. Serum creatinine, eGFR, endocrine hormone, and urea sodium excretion were not significantly correlated.

The increases in the serum sodium concentration were negatively associated with the basal sodium levels ($r = -0.546$, $p = 0.01$) (Fig. 3). The cases of hyponatremia were improved to the normal value.

Among 21 study participants, 2 patients discontinued tolvaptan treatment during the study periods because of liver dysfunction and cerebral infarction, respectively.

### Table 2 Change of clinical parameters after administration of tolvaptan

| Parameter                      | Baseline (median, IQR) | 1 week (median, IQR) | $p$ value |
|-------------------------------|------------------------|----------------------|-----------|
| Body weight (kg)              | 62.6 (54.6–72.5)       | 61.6 (47.7–70.9)     | $< 0.001$ |
| Average urinary volume (ml/day)| 975 (783–1350)         | 1426 (1079–1557)     | $< 0.001$ |
| Systolic blood pressure (mmHg)| 136 (126–143)          | 130 (119–147)        | 0.852     |
| Diastolic blood pressure (mmHg)| 74 (64–78)             | 68 (64–76)           | 0.794     |
| Urine gravity ($n = 19$)      | 1.011 (1.008–1.013)    | 1.009 (1.008–1.012)  | 0.172     |
| Serum creatine (mg/dl)        | 3.82 (3.48–5.08)       | 4.35 (3.74–5.45)     | $0.012$   |
| eGFR (ml/min/1.73 m$^2$)      | 11.6 (9.2–13.9)        | 9.8 (8.9–12.6)       | $0.008$   |
| Serum sodium (mEq/l)          | 139 (136–142)          | 141 (138–143)        | $0.002$   |
| Brain natriuretic peptide (pg/ml) | 488.9 (89.3–599.1)    | 337.0 (113.1–506.0)  | 0.117     |
| Atrial natriuretic peptide (pg/ml) ($n = 13$) | 104.0 (50.8–163.0)    | 99.9 (48.7–181.0)    | 0.576     |
| Antidiuretic hormone (pg/ml) ($n = 9$) | 2.9 (1.4–3.5)          | 4.2 (1.85–4.75)      | 0.735     |

$IQR$ interquartile range, $n$ number, $eGFR$ estimated glomerular filtration rate

### Discussion

In this study, we demonstrated that tolvaptan produced significant diuretic effects and reduced body weight in CKD patients. The urine osmolality was also decreased significantly. There was a slight increase in serum creatine level, but improvement for hyponatremia was observed. The reduction of body weight after administration of tolvaptan was correlated with the baseline urine volume, urine osmolality, and the IVCD, but not with renal function in the study subjects.

We confirmed that body weight decreased and urine volume increased by tolvaptan in advanced stages of CKD. Although the increase of urine volumes seen in those patients were lower than those in patients with normal
renal function [10, 11], it is effective to delay introducing renal replacement therapy. Even in the advanced stages of CKD, tubule-interstitial functions were reported as being maintained to a certain degree, particularly in the collecting ducts of the medullary area [12]. Collecting tubules are known as a low oxygen consumption tissue compared with the medullary thick ascending limb of Henle, which is the site of action of furosemide [13, 14], and is thought to be strong against hypoxic conditions. Thus, tolvaptan may work even if the kidney function decreased to the advanced stages of CKD. Furthermore, because tolvaptan is transported to collecting ducts without binding to proteins in blood, tolvaptan is not affected by serum or urine proteins levels as compared with furosemide [15–17]. It is also thought to be less susceptible to the glomerular filtration rate and urine flow, because it acts from the vascular side of principal cells of the collecting duct. Indeed, serum creatinine and eGFR were not correlated with diuretic effects in our study. Thus, tolvaptan may show diuretic effects in furosemide-resistant cases such as in advanced stages of CKD. Natriuretic effects of co-administering diuretics (i.e., furosemide) may also be enhanced due to the improvement of renal congestion by tolvaptan [18, 19]. Urinary excretion of sodium and FENa increased after tolvaptan treatment in our study, suggesting that furosemide resistance was improved. Moreover, plasma arginine vasopressin has stimulatory effects on epithelial Na-channel (ENaC)-mediated sodium reabsorption in the distal nephrons [20], and inhibition of V₂ receptors by tolvaptan decreases the ENaC activity and enhances excretion of sodium in urine [21].

Recent studies reported that increased expression of aquaporin-2 was observed in the epithelial cells of the collecting ducts of tolvaptan responders [12]. However, it is still unclear what clinical factors are associated with diuretic effects and weight reduction. Therefore, we examined predictors of effects of tolvaptan, which are often measured routinely in clinical settings. We found that the baseline urine osmolality, urine volume, and IVCD negatively correlated with body weight reduction after tolvaptan treatment. Urine osmolality was reported as a predictor of distinguishing responders from non-responders to tolvaptan in decompensated heart failure patients [22]. Similarly, a significant difference in the urine osmolalities before the tolvaptan treatment was observed between responders and non-responders in CKD patients [23]. The concentrated

| Parameter                              | rs  | p value |
|----------------------------------------|-----|---------|
| Body weight (kg)                       | -0.098 | 0.672   |
| Blood pressure (mmHg)                  |     |         |
| Systolic                               | 0.128 | 0.58    |
| Diastolic                              | -0.16 | 0.488   |
| Furosemide (mg/day)                    | -0.215 | 0.349   |
| Average urinary volume (ml/day)        | -0.48 | 0.028   |
| Ejection fraction (%) (n = 15)         | 0.066 | 0.815   |
| Inferior vena cava diameter (mm) (n = 14) | -0.622 | 0.017   |
| Urine gravity (n = 19)                 | -0.376 | 0.113   |
| Urine osmolality (mOsm/kg) (n = 19)    | -0.479 | 0.038   |
| U-Na (mEq/gCr) (n = 20)                | -0.263 | 0.282   |
| FENa (%) (n = 20)                      | -0.04  | 0.867   |
| Serum creatinine                       | 0.113 | 0.626   |
| eGFR (ml/min/1.73 m²)                  | -0.034 | 0.884   |
| Serum sodium (mEq/l)                   | -0.093 | 0.689   |
| Serum osmolality (mOsm/kg) (n = 18)    | -0.236 | 0.345   |
| Brain natriuretic peptide (pg/ml) (n = 20) | -0.229 | 0.317   |
| Atrial natriuretic peptide (pg/ml) (n = 13) | -0.412 | 0.162   |
| Antidiuretic hormone (pg/ml) (n = 9)   | -0.561 | 0.116   |

rs, Spearman’s rank correlation coefficient, n number, U-Na urine sodium excretion, FENa fractional excretion of sodium, eGFR estimated glomerular filtration rate

Fig. 2 Correlations between diuretic effects of tolvaptan and body weight in CKD patients. The alteration of body weight after 1 week negatively correlated with the baseline urine osmolality (n = 19), urine volume (n = 21), and IVCD (n = 14)
urine suggests that the function of collecting ducts remains. Moreover, when there was no or only mild tubule-interstitial damage in the kidney biopsies, it has been reported that tolvaptan was effective even when glomerulosclerosis was present [12]. Thus, if the high urine osmolality remained, tolvaptan would demonstrate significant diuretic effects in cases with complicating renal failure. Apart from the urine osmolality, the baseline urine volume and IVCD also correlated with the alteration of body weight in this study. The high urine volume and enlarged IVCD suggest an increased intravascular fluid volume. Therefore, we estimate that diuretic effects are obtainable in these cases.

In cases of hyponatremia, the serum sodium concentration was markedly improved. Similar to our report, there was a study reporting that changes in serum sodium concentrations after tolvaptan treatment inversely correlated with their baseline values [24]. This study included a case with relative excess secretion of vasopressin in spite of hyponatremia (serum sodium 121 mEq/l, serum osmolality 258 mOsm/kg, ADH 1.0 pg/ml). Furthermore, the serum sodium markedly increased in this case; the increase of serum sodium was 20 mEq/l within 1 week. The negative correlation between baseline serum sodium concentrations and increments of serum sodium concentrations after tolvaptan treatment remained even if we excluded this case ($r = -0.472, p = 0.036$). Fortunately, the adverse event had not occurred in the case. However, we should pay attention to the doses of tolvaptan in the case of hyponatremia, because there is a risk of osmotic demyelination syndrome with rapid correction of serum sodium concentrations. As ADH secretion was enhanced in patients with heart failure [25], it is possible that cases with excess secretion of ADH are included in the study populations. For this reason, there may be a corrective effect for hyponatremia. Therefore, tolvaptan may be a suitable drug for combination treatments with diuretics in CKD patients with refractory chronic heart failure (CHF). On the other hand, hyponatremia was considered to be a factor of poor prognosis in cases with CKD and CHF [26], and such hyponatremic patients were known for having risks of incidental fall and bone fracture [27], which causes long-term hospitalization and deterioration of quality of life. Therefore, it is reasonable to choose tolvaptan for treating CKD with hyponatremia.

Two cases were not able to continue use of tolvaptan because of its side effects. One patient exhibited liver dysfunction. Similarly, in the study of patients with autosomal dominant polycystic kidney disease, it was also reported that patients receiving tolvaptan had an increased risk of alanine aminotransferase or aspartate aminotransferase level elevation [35]. The other patient developed cerebral infarction. The mild hemiplegia symptom developed on the fourth day, and a small infarction lesion was detected by CT examination.
associated with tolvaptan, even in the above clinical trials [35]. They were not fatal clinical conditions, but caution and accumulation of further cases are required.

This study has several limitations. As there were inconsistencies in the timing of cardiac echo (several days before administration, at the start of tolvaptan, etc), the CHF status might not be evaluated precisely. Furthermore, this is a retrospective observational study with a relatively small number of patients. It is necessary to examine the plasticity in more cases to warrant the results. A prospective study in which patients are randomized to comparison groups with placebo or other diuretics is expected to confirm our results.

In conclusion, tolvaptan has diuretic effects in cases with complicated, advanced renal dysfunction corresponding to stage 3–5 CKD, and is also effective in correcting hyponatremia. As the baseline urine osmolality, urine volume, and IVCD correlated closely with the amount of reduction in body weight, they may be useful predictors for diuretic effects of tolvaptan. In cases of maintaining urine concentrating abilities, tolvaptan may be the treatment of choice for CKD patients with fluid retention.

Compliance with ethical standards

Conflict of interest The contributing authors reported the following financial supports: Nobuhiro Hirawa received scholarship donations from Pfizer Pharmaceutical, and Otsuka Pharmaceutical. Koichi Tamura received research funding from AstraZeneca, Ono Pharmaceutical, and Tsumura. Satoshi Umemura received lecture fees from Takeda, Behringer, Daiichi-Sankyo, MSD, Shionogi, and Kyouwhakai Pharmaceutical, and Tsumura. Satoshi Umemura received research funding from AstraZeneca, Ono Pharmaceutical, and Otsuka Pharmaceutical. Koichi Tamura received research funding from AstraZeneca, Ono Pharmaceutical, and Tsumura. Satoshi Umemura received lecture fees from Takeda, Behringer, Daiichi-Sankyo, Novartis, Astorazeneika, Kowa, Shionogi, and MSD.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies conducted (IRB Approval Number B160700018).

Informed consent We obtained consent through opt-out procedure from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, et al. Vasopressin V2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273–8.
2. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquerectic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860–7.
3. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690–6.
4. Gheorghiade M, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin V2-receptor antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–71.
5. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.
6. Miyazaki T, Yamamura Y, Onogawa T, Nakamura S, Kinoshita S, Nakayama S, et al. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology. 2005;146:3037–43.
7. Felker GM, O’Connor CM, Braunwald E. Heart Failure Clinical Research Network, I. Loop diuretics in acute decompensated heart failure: necessary? Necessary evil? Circ Heart Fail. 2009;2:56–62.
8. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
9. Cheriex EC, Leunissen KM, Janssen JH, Mooy JM, van Hooff JP. Echography of the inferior vena cava is a simple and reliable tool for estimation of ‘dry weight’ in haemodialysis patients. Nephrol Dial Transplant. 1989;4:563–8.
10. Matsuoka M, Hori M, Izuimi T, Asanai H, Tsutamoto T, Tolvaptan I. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S19–31.
11. Matsuoka M, Hori M, Izuimi T, Fukunumi M, Tolvaptan I. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl 1):S33–45.
12. Sato E, Nakamura T, Amaha M, Nomura M, Matsumura D, Yamagishi H, et al. Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure. Int Heart J. 2014;55:533–8.
13. Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol. 1999;34:685–91.
14. Goldfarb M, Abassi Z, Rosen S, Shina A, Brezis M, Heyman SN. Compensated heart failure predisposes to outer medullary tubular injury: studies in rats. Kidney Int. 2001;60:607–13.
15. Tanaka A, Katsuos T, Ozaki T, Sakata F, Kato N, Suzuki Y, et al. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients. Acta Cardiol. 2015;70:217–23.
16. Inoue M, Okajima K, Hirao T, Ando Y, Watanabe N, Yasaka T, et al. Mechanism of furosemide resistance in analbuminuric rats and hypoalbuminemic patients. Kidney Int. 1987;32:198–203.
17. Kirchner KA, Voelker JR, Brater DC. Intratubular albumin blunts the response to furosemide—a mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther. 1990;252:1097–101.
18. Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol. 2013;17:834–8.

19. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96.

20. Blanchard A, Frank M, Wuerzner G, Peyrard S, Bankir L, Jeunemaitre X, et al. Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent. Clin J Am Soc Nephrol. 2011;6:753–9.

21. Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, et al. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist. Int Heart J. 2014;55:131–7.

22. Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, et al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J. 2013;77:1208–13.

23. Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R, Hamano T, Rakugi H, et al. Urine osmolality predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. Nephron. 2015;130:10–12.

24. Watanabe K, Dohi K, Sugimoto T, Ichikawa K, Morita T, Misawa T, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol. 2016;67:399–405.

25. Suzuki S, Yoshiiha A, Yamaki T, Sugimoto K, Kunii H, Nakamoto K, et al. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol. 2013;53:1277–85.

26. Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hyper tens Res. 2008;31:433–41.

27. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Gran tham JJ, Higashiara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–18.